Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

15.96CHF
2:24pm BST
Change (% chg)

CHF-0.02 (-0.13%)
Prev Close
CHF15.98
Open
CHF15.98
Day's High
CHF16.00
Day's Low
CHF15.70
Volume
9,351
Avg. Vol
11,552
52-wk High
CHF41.15
52-wk Low
CHF14.52

Chart for

About

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF237.58
Shares Outstanding(Mil.): 6.29
Dividend: --
Yield (%): --

Financials

  SANN.S Industry Sector
P/E (TTM): -- 30.92 33.69
EPS (TTM): -6.40 -- --
ROI: -37.59 14.76 14.30
ROE: -55.62 16.26 16.03

BRIEF-Santhera Gets Positive Opinion For Orphan Drug Designation In EU For Pol6014 In Cystic Fibrosis

* SANTHERA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR POL6014 IN CYSTIC FIBROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Oct 2018

BRIEF-Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike

* SAYS EXPECTS 50 MILLION SFR SALES OF RAXONE WITHIN 2-3 YEARS‍​

04 Sep 2018

Swiss stocks - Factors to watch on Sept 4

ZURICH, Sept 4 The Swiss blue-chip SMI was seen opening 0.1 percent higher at 9,016 points on Tuesday, according to premarket indications by bank Julius Baer .

04 Sep 2018

Santhera lifts forecast amid cash burn, trial setbacks

ZURICH, Sept 4 Santhera lifted its full-year 2018 sales forecast slightly but quickly drew down cash reserves in the first half, as the Swiss drugmaker continued efforts to make a success of its main drug despite regulatory and trial setbacks.

04 Sep 2018

BRIEF-Santhera Pharmaceuticals Holding H1 Net Result Of CHF -27.4 Mln

* 1H 2018 SALES OF CHF 16.0 MILLION, INCREASE OF 48% COMPARED TO 1H 2017

04 Sep 2018

Swiss stocks - Factors to watch on June 22

ZURICH, June 22 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8473 points on Friday, according to premarket indications by bank Julius Baer .

22 Jun 2018

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

22 Jun 2018

BRIEF-Santhera Submits NDA In South Korea For Raxone For The Treatment Of LHON

* SANTHERA SUBMITS NDA IN SOUTH KOREA FOR RAXONE® FOR THE TREATMENT OF LHON

12 Jun 2018

Earnings vs. Estimates